Almost half of those stopping GLP-1 weight-loss drugs keep the weight off

• A real-world study followed individuals who started GLP-1 medications and discontinued them within 3 to 12 months to assess weight changes after stopping treatment.
• Before stopping the medications, people treated for obesity lost about 8.4% of their body weight, while those treated for type 2 diabetes lost about 4.4% on average.
• One year after discontinuation, average weight regain was small. People in the obesity group regained about 0.5%, while those in the diabetes group lost an additional 1.3% on average, though individual outcomes varied.
• Many people continued other forms of treatment after stopping GLP-1 drugs, which may help explain why large weight regain was not commonly observed.

GLP-1 receptor agonists are medications people may use to manage obesity and type 2 diabetes. These drugs mimic the hormone glucagon-like peptide-1, which helps regulate blood sugar, slow stomach emptying, and reduce appetite.

Two widely prescribed examples include semaglutide and tirzepatide. Both have gained global attention for their ability to potentially aid substantial weight loss. However, various factors, such as possible side effects and costs, may lead to discontinuation of these drugs.

Thus, questions remain about what happens when individuals stop taking these medications. Some research suggests that cessation is often followed by rapid weight regain and reversal of beneficial health effects.

However, a new study, published in Diabetes, Obesity and Metabolism, indicates that people may maintain much of their weight loss after discontinuation, particularly if they transition to other treatments or lifestyle support.